Literature DB >> 21138381

Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration.

Davina Swan1, Jean Long, Olivia Carr, Jean Flanagan, Helena Irish, Shay Keating, Michelle Keaveney, John Lambert, P Aiden McCormick, Susan McKiernan, John Moloney, Nicola Perry, Walter Cullen.   

Abstract

Hepatitis C (HCV) infection is common among injecting drug users (IDUs), yet accessing of HCV care, particularly HCV treatment, is suboptimal. There has been little in-depth study of IDUs experiences of what enables or prevents them engaging at every level of HCV care, including testing, follow-up, management and treatment processes. This qualitative study aimed to explore these issues with current and former IDUs in the greater Dublin area, Ireland. From September 2007 to September 2008 in-depth interviews were conducted with 36 service-users across a range of primary and secondary care services, including: two addiction clinics, a general practice, a community drop-in center, two hepatology clinics, and an infectious diseases clinic. Interviews were analyzed using a grounded theory approach. Barriers to HCV care included perceptions of HCV infection as relatively benign, fear of investigations and treatment, and feeling well. Perceptions were shaped by the discourse about HCV and "horror stories" about the liver biopsy and treatment within their peer networks. Difficulties accessing HCV care included limited knowledge of testing sites, not being referred for specialist investigations and ineligibility for treatment. Employment, education, and addiction were priorities that competed with HCV care. Relationships with health care providers influenced engagement with care: Trust in providers, concern for the service-user, and continuity of care fostered engagement. Education on HCV infection, investigations, and treatment altered perceptions. Becoming symptomatic, responsibilities for children, and wanting to move on from drug use motivated HCV treatment. In conclusion, IDUs face multiple barriers to HCV care. A range of facilitators were identified that could inform future interventions.

Entities:  

Mesh:

Year:  2010        PMID: 21138381     DOI: 10.1089/apc.2010.0142

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  73 in total

1.  Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels.

Authors:  Bryce D Smith; Anthony K Yartel
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

2.  Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada.

Authors:  Samantha Young; Evan Wood; M-J Milloy; Kora DeBeck; Sabina Dobrer; Ekaterina Nosova; Thomas Kerr; Kanna Hayashi PhD
Journal:  Subst Abus       Date:  2018-10-02       Impact factor: 3.716

3.  Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program.

Authors:  Stacey B Trooskin; Joanna Poceta; Caitlin M Towey; Annajane Yolken; Jennifer S Rose; Najia L Luqman; Ta-Wanda L Preston; Philip A Chan; Curt Beckwith; Sophie C Feller; Hwajin Lee; Amy S Nunn
Journal:  J Gen Intern Med       Date:  2015-02-14       Impact factor: 5.128

4.  Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.

Authors:  Jason Grebely; Lucy Tran; Louisa Degenhardt; Alexander Dowell-Day; Thomas Santo; Sarah Larney; Matthew Hickman; Peter Vickerman; Clare French; Kerryn Butler; Daisy Gibbs; Heather Valerio; Phillip Read; Gregory J Dore; Behzad Hajarizadeh
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

5.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

6.  Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

Authors:  April M Young; Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Dustin B Stephens; Jennifer R Havens
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

7.  HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.

Authors:  Tessa M Nápoles; Abigail W Batchelder; Ada Lin; Lissa Moran; Mallory O Johnson; Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Kellene V Eagen; Elise D Riley
Journal:  J Public Health (Oxf)       Date:  2019-12-20       Impact factor: 2.341

8.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

9.  Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status.

Authors:  Dustin B Stephens; Jennifer R Havens
Journal:  J Stud Alcohol Drugs       Date:  2013-05       Impact factor: 2.582

10.  Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting.

Authors:  Linwei Wang; Dimitra Panagiotoglou; Jeong Eun Min; Kora DeBeck; M J Milloy; Thomas Kerr; Kanna Hayashi; Bohdan Nosyk
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.